Physician profile
Robert Stover
NPI 1447735147
$3,595.76
in general payments reported to CMS, 2019-2025
20 companies · $485 in 2025
The $485 reported for 2025 was more than what 76% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $887 · 2020: $184 · 2021: $1,022 · 2022: $397 · 2023: $483 · 2024: $138 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,106.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,239.46 | 2019-2025 | Dailies Total1, Total30, Precision 1 |
| Bausch & Lomb Americas INC. | $520.21 | 2022-2025 | Infuse, Miebo |
| Allergan, INC. | $224.98 | 2020-2021 | |
| Johnson & Johnson Vision Care, INC. | $217.66 | 2023-2025 | Acuvue |
| Aerie Pharmaceuticals, INC. | $190.32 | 2021 | |
| Glaukos Corporation | $183.56 | 2021 | |
| Eyevance Pharmaceuticals LLC | $136.64 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $123.23 | 2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $120.79 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $118.13 | 2019-2021 | |
| Horizon Therapeutics Plc | $98.71 | 2022 | |
| Novartis Pharmaceuticals Corporation | $92.58 | 2020-2021 | |
| Coopervision INC. | $83.41 | 2023 | Misight Contact Lens |
| Sight Sciences, INC. | $69.89 | 2021 | |
| Abbvie INC. | $42.36 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $39.71 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $35.45 | 2022 | |
| Ivantis, INC | $23.27 | 2021 | |
| Akorn Operating Company LLC | $18.87 | 2021 | |
| Shire North American Group INC | $16.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Stover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.